Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 9, 2013, Pages 1302-1311

  Manca, Maria L ^a   Cassano, Roberta ^b   Valenti, Donatella ^a   Trombino, Sonia ^b   Ferrarelli, Teresa ^b   Picci, Nevio ^b   Fadda, Anna M ^a   Manconi, Maria ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Department Scienze Farmaceutiche ^*  (Italy)

Author keywords

A549 cells; antimicobacterial drugs; microparticles; pulmonary drug delivery; toxicity studies

Indexed keywords

GELATIN; ISONIAZID; PRODRUG; RIFAMPICIN;

AEROSOL; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; COVALENT BOND; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STRUCTURE; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LUNG ALVEOLUS EPITHELIUM; NEBULIZATION; PARTICLE SIZE; SPRAY DRYING; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 84881479792     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12094     Document Type: Article

References (37)

1. Russell DG,. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2001; 2: 569-586.
2. Clemens DL,. Characterization of the Mycobacterium tuberculosis phagosome. Trends Microbiol 1996; 4: 113-118. (Pubitemid 26104771)
3. Deretic V, Fratti RA,. Mycobacterium tuberculosis phagosome. Mol Microbiol 1999; 31: 1603-1609. (Pubitemid 29151262)
4. Vergne I, et al. Mycobacterium tuberculosis phagosome maturation arrest: selective targeting of PI3P-dependent membrane trafficking. Traffic 2003; 4: 600-606. (Pubitemid 37062683)
5. Manca ML, et al. PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery? A comparative study of particle stability during nebulization. Colloids Surf B 2008; 62: 220-231.
6. Manca ML, et al. Release of rifampicin from chitosan, PLGA and chitosan-coated PLGA microparticles. Colloids Surf B 2008; 67: 166-170.
7. Zaru M, et al. Chitosan-coated liposomes for delivery to lungs by nebulisation. Colloids Surf B 2009; 71: 88-95.
8. Marianecci C, et al. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts. J Control Release 2010; 147: 127-135.
9. Mura S, et al. Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. Biomacromolecules 2011; 12: 4136-4143.
10. Cassano R, et al. Respirable rifampicin-based microspheres containing isoniazid for tuberculosis treatment. J Biomed Mater Res A 2012; 100A: 536-542.
11. Ungaro F, et al. Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. J Pharm Pharmacol 2012; 64: 1217-1235.
12. Pinheiro M, et al. Liposomes as drug delivery systems for the treatment of TB. Nanomedicine 2011; 6: 1413-1428.
13. Kurmi B, et al. Micro- and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 2012; 7: 781-794.
14. Cassano R, et al. Synthesis and in vitro antitubercular activity of isoniazid-gelatin conjugate. J Pharm Pharmacol 2012; 64: 712-718.
15. Xia W, et al. Tissue engineering of cartilage with the use of chitosan-gelatin complex scaffolds. J Biomed Mater Res B 2004; 71B: 373-380. (Pubitemid 39463774)
16. Dainiak M, et al. Gelatin-fibrinogen cryogel dermal matrices for wound repair: preparation, optimisation and in vitro study. Biomaterials 2010; 31: 67-76.
17. Tseng CL, et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008; 20: 3014-3022.
18. Morimoto K, et al. Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J Pharm Pharmacol 2000; 52: 611-617. (Pubitemid 30410073)
19. Cremers H, et al. Albumin-heparin microspheres as carriers for cytostatic agents. J Control Release 1990; 11: 167-179. (Pubitemid 20070095)
20. Singh R, et al. Particle-size analysis of tomato powder. J Food Process Pres 2006; 30: 87-98.
21. Harding SE,. On the hydrodynamic analysis of macromolecular conformation. Biophys Chem 1995; 55: 69-93.
22. Verma R, et al. Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems. Ther Deliv 2011; 2: 753-768.
23. Gaihre B, et al. Gelatin coated magnetic iron oxide nanoparticles as carrier system: drug loading and in vitro drug release study. Int J Pharm 2009; 365: 180-189.
24. Ugwoke MI, et al. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005; 57: 1640-1665. (Pubitemid 41443473)
25. Albeiicio F, et al. New trends in peptide coupling reagents. Org Prep Proced Int 2001; 33: 203-303.
26. Alpar HO, et al. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 2005; 57: 411-430. (Pubitemid 39550968)
27. Bridges PA, Taylor KM,. Evaluating the controlled release properties of inhaled nanoparticles using isolated, perfused, and ventilated lung models. Int J Pharm 2000; 204: 69-79.
28. Manca ML, et al. Liposomes coated with chitosan-xanthan gum (chitosomes) as potential carriers for pulmonary delivery of rifampicin. J Pharm Sci 2012; 101: 566-575.
29. Taylor K, et al. The stability of liposomes to nebulisation. Int J Pharm 1990; 58: 57-61. (Pubitemid 20034228)
30. Desai TR, et al. A facile method of delivery of liposomes by nebulization. J Control Release 2002; 84: 69-78. (Pubitemid 35223415)
31. Zaru M, et al. Rifampicin loading liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation. J Liposome Res 2009; 19: 68-76.
32. Albasarah Y, et al. Chitosan-coated antifungal formulations for nebulisation. J Pharm Pharmacol 2010; 62: 821-828.
33. Bermudez LE, Goodman J,. Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect Immun 1996; 64: 1400-1406. (Pubitemid 26102407)
34. Mehta PK, et al. Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication. Infect Immun 1996; 64: 2673-2679. (Pubitemid 26226832)
35. Zaru M, et al. Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm 2007; 67: 655-666. (Pubitemid 47576612)
36. Manconi M, et al. Intracellular distribution of fluorescent probes delivered by vesicles of different lipidic composition. Colloids Surf B 2007; 57: 143-151. (Pubitemid 46671506)
37. Lee R, et al. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci Rep 1998; 18: 69-78. (Pubitemid 28438379)